BioCentury | Oct 28, 2020
Product Development

Data Byte: FOLR1 pipeline for cancer

At least four antibody-drug conjugates, one antibody and two vaccines targeting FOLR1 are in development to treat cancer. The lead program is in Phase III testing for ovarian cancer. ImmunoGen Inc. (NASDAQ:IMGN) expects data next year from the...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

AAV gene editing therapy for Angelman syndromeUniversity of North Carolina at Chapel Hill scientists have created a CRISPR gene therapy for Angelman syndrome that ameliorated motor function deficits in a mouse model of the maternally...
BioCentury | Oct 19, 2020

ImmunoGen chooses Huadong’s $40M upfront offer for Greater China rights to ADC

ImmunoGen has been signaling for months that it would soon strike a licensing deal in China for its lead antibody-drug conjugate. On Monday, the biotech said Huadong will gain the program’s rights for $40 million...
BioCentury | Oct 14, 2020
Product Development

A third leading COVID program enters holding pattern as NIH pauses testing of Lilly’s mAb

The launch of NIH’s Phase II ACTIV-5 Big Effect Trial study of anti-inflammatory mAbs Skyrizi from AbbVie and Boehringer and lenzilumab from Humanigen to treat hospitalized COVID-19 patients has coincided...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Small molecule kinase inhibitor for cystic fibrosis with splicing mutation

DISEASE CATEGORY: Pulmonary INDICATION: Cystic fibrosis (CF) A small molecule inhibitor of four kinases that regulate splicing could treat CF caused by the most common disease-associated CFTR splicing...
BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

Limiting the inflammatory side effects of adjuvanted vaccinesA team led by University of Chicago scientists reported in Science Advances that NF-κB modulator SN50 could enable the use of adjuvants to amplify adaptive immune response by...
BioCentury | Sep 2, 2020
Product Development

COVID-19 Quick Takes: NAS framework on vaccine allocation prioritizes higher risk groups

Framework to allocate vaccinesA discussion draft of a framework on equitable allocation of COVID-19 vaccines released by The National Academies of Sciences, Engineering and Medicine proposes...
BioCentury | Aug 25, 2020

$155M Perceptive-led note deal enables Kronos to fund newly acquired Gilead asset’s pivotal trial

After acquiring a Phase III-ready asset from Gilead last month, Kronos raised $155 million on Monday to fund the cancer therapy’s registrational trial, slated for 2021. The funding will also enable Kronos, led by Gilead...
BioCentury | Aug 14, 2020

Non-European venture investment in European biotech is on the rise

European biotechs are seeing more participation by non-European investors in venture rounds than they’ve seen in the last three years, and the median size of the financings has outstripped solely...
BioCentury | Jul 30, 2020
Product Development

Finding immunosuppression sweet spot could be next up for COVID-19 after second IL-6 failure

A Phase III miss for a second IL-6 inhibitor in COVID-19 patients could be the death knell for the drug class in the disease. But the mortality benefit demonstrated by dexamethasone suggests a broader immunosuppressive...
Items per page:
1 - 10 of 611